Compare BridgeBio Pharma Inc (BBIO) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VanEck Gold Miners ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while VanEck Gold Miners ETF trades at $91.08. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | GDX | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $115.84 |
52-Week Low | $47.29 | $56.60 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
GDX trades at $89.84, up 7.09% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's rally and strong miner earnings, though financial ratios are unavailable. The ETF offers diversified exposure to gold mining equities, benefiting from high gold prices and institutional interest.
Outlook is positive due to gold's strength and sector momentum, but risks include volatility from gold price swings and competition from physical gold ETFs. Analyst sentiment is mixed, with some seeing value in miners' underperformance relative to gold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
